ALMS

SEC source: 0001231919-26-001158 · form4-09102026_010944.xml · nonDerivative · entry 6

AKKARAJU SRINIVAS · CIK 0001253170 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara Opportunity Fund, L.P.

Disclosed balance after: 2,298,783

F4 · kind: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs.

F6 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.26 to $10.835, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

SEC source: 0001231919-26-001158 · form4-09102026_010944.xml · nonDerivative · entry 5

AKKARAJU SRINIVAS · CIK 0001253170 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara BioCapital, L.P.

Disclosed balance after: 4,937,026

F4 · kind: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs.

F6 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.26 to $10.835, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001231919-26-001158 · form4-09102026_010944.xml · nonDerivative · entry 4

AKKARAJU SRINIVAS · CIK 0001253170 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara Opportunity Fund, L.P.

Disclosed balance after: 2,025,493

F4 · kind: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs.

F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $10.38 to $10.91, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

SEC source: 0001231919-26-001158 · form4-09102026_010944.xml · nonDerivative · entry 3

AKKARAJU SRINIVAS · CIK 0001253170 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara BioCapital, L.P.

Disclosed balance after: 4,663,735

F4 · kind: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs.

F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $10.38 to $10.91, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001231919-26-001158 · form4-09102026_010944.xml · nonDerivative · entry 2

AKKARAJU SRINIVAS · CIK 0001253170 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara Opportunity Fund, L.P.

Disclosed balance after: 2,073,558

F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.02 to $11.60, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

SEC source: 0001231919-26-001158 · form4-09102026_010944.xml · nonDerivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara BioCapital, L.P.

Disclosed balance after: 4,711,801

F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.02 to $11.60, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0002023806-26-000007 · form4-08052026_100826.xml · nonDerivative · entry 1

Pangali Sanam · CIK 0002023806 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,747

F1 · shares: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units granted on July 29, 2025, and does not represent a discretionary sale by the Reporting Person.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.62 to $26.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002023657-26-000005 · form4-08052026_100817.xml · nonDerivative · entry 1

Bradley Mark Christopher · CIK 0002023657 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,533

F1 · shares: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units granted on July 29, 2025, and does not represent a discretionary sale by the Reporting Person.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.60 to $26.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes 2,377 shares acquired on May 20, 2026 under the Issuer's 2024 Employee Stock Purchase Plan.

SEC source: 0001744578-26-000005 · form4-08052026_100820.xml · nonDerivative · entry 1

Schroer John R. · CIK 0001744578 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,718

F1 · shares: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units granted on July 29, 2025, and does not represent a discretionary sale by the Reporting Person.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.56 to $26.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001506218-26-000005 · form4-08052026_100804.xml · nonDerivative · entry 1

Hardiman Roy C. · CIK 0001506218 · Chief Business & Strategy Ofcr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 207,746

F1 · shares: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units granted on July 29, 2025, and does not represent a discretionary sale by the Reporting Person.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.62 to $26.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes 1,037 shares acquired on November 20, 2025 and 3,000 shares acquired on May 20, 2026 under the Issuer's 2024 Employee Stock Purchase Plan.

SEC source: 0001751719-26-000008 · form4-08052026_100849.xml · nonDerivative · entry 1

Goldstein David M · CIK 0001751719 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,970

F1 · shares: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units granted on July 29, 2025, and does not represent a discretionary sale by the Reporting Person.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.61 to $26.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes 2,177 shares acquired on May 20, 2026 under the Issuer's 2024 Employee Stock Purchase Plan.

SEC source: 0001789317-26-000007 · form4-08052026_100847.xml · nonDerivative · entry 1

Drappa Jorn · CIK 0001789317 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,892

F1 · shares: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units granted on July 29, 2025, and does not represent a discretionary sale by the Reporting Person.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.54 to $26.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002023806-26-000005 · form4-07082026_080749.xml · derivative · entry 3

Pangali Sanam · CIK 0002023806 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 5,000 shares

Expires 2035-02-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares underlying this option vested on February 18, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date.

SEC source: 0002023806-26-000005 · form4-07082026_080749.xml · nonDerivative · entry 2

Pangali Sanam · CIK 0002023806 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,111

SEC source: 0002023806-26-000005 · form4-07082026_080749.xml · nonDerivative · entry 1

Pangali Sanam · CIK 0002023806 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,111

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001645512-26-000003 · form4-07022026_100712.xml · derivative · entry 2

TETRAULT LYNN A. · CIK 0001645512 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,528

Underlying: Common Stock · 15,528 shares

Expires 2036-06-29

F2 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

SEC source: 0001645512-26-000003 · form4-07022026_100712.xml · nonDerivative · entry 1

TETRAULT LYNN A. · CIK 0001645512 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,553

F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

SEC source: 0001326228-26-000004 · form4-07022026_100738.xml · derivative · entry 2

Yao Zhengbin · CIK 0001326228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,528

Underlying: Common Stock · 15,528 shares

Expires 2036-06-29

F2 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

SEC source: 0001326228-26-000004 · form4-07022026_100738.xml · nonDerivative · entry 1

Yao Zhengbin · CIK 0001326228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,082

F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

SEC source: 0001311210-26-000006 · form4-07022026_100719.xml · derivative · entry 3

Machado Patrick · CIK 0001311210 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,528

Underlying: Common Stock · 15,528 shares

Expires 2036-06-29

F3 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

SEC source: 0001311210-26-000006 · form4-07022026_100719.xml · nonDerivative · entry 1

Machado Patrick · CIK 0001311210 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,553

F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

SEC source: 0001569226-26-000005 · form4-07022026_100741.xml · derivative · entry 2

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,528

Underlying: Common Stock · 15,528 shares

Expires 2036-06-29

F2 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

SEC source: 0001569226-26-000005 · form4-07022026_100741.xml · nonDerivative · entry 1

Srivastava Sapna · CIK 0001569226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,553

F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

SEC source: 0001253170-26-000011 · form4-07022026_100705.xml · derivative · entry 4

AKKARAJU SRINIVAS · CIK 0001253170 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,528

Underlying: Common Stock · 15,528 shares

Expires 2036-06-29

F4 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

SEC source: 0001253170-26-000011 · form4-07022026_100705.xml · nonDerivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,553

F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

SEC source: 0001789317-26-000005 · form4-05272026_110540.xml · derivative · entry 4

Drappa Jorn · CIK 0001789317 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,465

Underlying: Common Stock · 15,535 shares

Expires 2035-02-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares underlying this option vested on February 18, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001789317-26-000005 · form4-05272026_110540.xml · derivative · entry 3

Drappa Jorn · CIK 0001789317 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,805

Underlying: Common Stock · 11,317 shares

Expires 2032-08-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25% of the shares underlying this option vested on August 22, 2023, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001789317-26-000005 · form4-05272026_110540.xml · nonDerivative · entry 2

Drappa Jorn · CIK 0001789317 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,339

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001789317-26-000005 · form4-05272026_110540.xml · nonDerivative · entry 1

Drappa Jorn · CIK 0001789317 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,804

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,037 shares acquired on November 20, 2025 and 3,000 shares acquired on May 20, 2026 under the Issuer's 2024 Employee Stock Purchase Plan.

SEC source: 0001104659-26-039611 · tm2611109-3_4seq1.xml · nonDerivative · entry 4

Foresite Labs, LLC · CIK 0002027905 · 10% owner

Foresite Labs Affiliates 2021, LLC · CIK 0002028005 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 680,486

F6 · kind: Represents shares received by TFL Investment Holdings, LLC ("TFL"). pursuant to pro rata distributions by Labs, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act.

F7 · ownership.nature: The shares are held of record by TFL. Tananbaum is the manager of TFL, and James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust, of which Tananbaum is a trustee, is the sole member of TFL. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.

SEC source: 0001104659-26-039611 · tm2611109-3_4seq1.xml · nonDerivative · entry 3

Foresite Labs, LLC · CIK 0002027905 · 10% owner

Foresite Labs Affiliates 2021, LLC · CIK 0002028005 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F5 · kind: Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Labs to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act.

F4 · ownership.nature: The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares.

SEC source: 0001104659-26-039611 · tm2611109-3_4seq1.xml · nonDerivative · entry 2

Foresite Labs, LLC · CIK 0002027905 · 10% owner

Foresite Labs Affiliates 2021, LLC · CIK 0002028005 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,123,337

F3 · kind: Represents shares received by Labs pursuant to pro rata distributions by Labs Affiliates, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act.

F4 · ownership.nature: The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares.

SEC source: 0001104659-26-039611 · tm2611109-3_4seq1.xml · nonDerivative · entry 1

Foresite Labs, LLC · CIK 0002027905 · 10% owner

Foresite Labs Affiliates 2021, LLC · CIK 0002028005 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · kind: Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Foresite Labs Affiliates 2021, LLC ("Labs Affiliates") to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · ownership.nature: The shares are held of record by Labs Affiliates. Foresite Labs, LLC ("Labs") is the managing member of Labs Affiliates and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), a manager of Labs, may be deemed to share voting and dispositive power over such shares.

SEC source: 0001104659-26-039610 · tm2611109-2_4seq1.xml · nonDerivative · entry 4

Foresite Capital Management VI LLC · CIK 0002013341 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital Fund VI LP · CIK 0001932516 · 10% owner

Labs Co-Invest V, LLC · CIK 0001810063 · 10% owner

Foresite Labs Management I, LLC · CIK 0001848577 · 10% owner

Foresite Labs Fund I, L.P. · CIK 0001848472 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 680,486

F6 · kind: Represents shares received by TFL Investment Holdings, LLC ("TFL"). pursuant to pro rata distributions by Labs, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act.

F7 · ownership.nature: The shares are held of record by TFL. Tananbaum is the manager of TFL, and James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust, of which Tananbaum is a trustee, is the sole member of TFL. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.

SEC source: 0001104659-26-039610 · tm2611109-2_4seq1.xml · nonDerivative · entry 3

Foresite Capital Management VI LLC · CIK 0002013341 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital Fund VI LP · CIK 0001932516 · 10% owner

Labs Co-Invest V, LLC · CIK 0001810063 · 10% owner

Foresite Labs Management I, LLC · CIK 0001848577 · 10% owner

Foresite Labs Fund I, L.P. · CIK 0001848472 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F5 · kind: Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Labs to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act.

F4 · ownership.nature: The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs, except to the extent of such person's pecuniary interest in such securities.

SEC source: 0001104659-26-039610 · tm2611109-2_4seq1.xml · nonDerivative · entry 2

Foresite Capital Management VI LLC · CIK 0002013341 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital Fund VI LP · CIK 0001932516 · 10% owner

Labs Co-Invest V, LLC · CIK 0001810063 · 10% owner

Foresite Labs Management I, LLC · CIK 0001848577 · 10% owner

Foresite Labs Fund I, L.P. · CIK 0001848472 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,123,337

F3 · kind: Represents shares received by Labs pursuant to pro rata distributions by Labs Affiliates, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act.

F4 · ownership.nature: The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs, except to the extent of such person's pecuniary interest in such securities.

SEC source: 0001104659-26-039610 · tm2611109-2_4seq1.xml · nonDerivative · entry 1

Foresite Capital Management VI LLC · CIK 0002013341 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner

Foresite Capital Fund VI LP · CIK 0001932516 · 10% owner

Labs Co-Invest V, LLC · CIK 0001810063 · 10% owner

Foresite Labs Management I, LLC · CIK 0001848577 · 10% owner

Foresite Labs Fund I, L.P. · CIK 0001848472 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · kind: Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Foresite Labs Affiliates 2021, LLC ("Labs Affiliates") to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · ownership.nature: The shares are held of record by Labs Affiliates. Foresite Labs, LLC ("Labs") is the managing member of Labs Affiliates and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), a manager of Labs, may be deemed to share voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs Affiliates, except to the extent of such person's pecuniary interest in such securities.

SEC source: 0001104659-26-039609 · tm2611109-1_4seq1.xml · nonDerivative · entry 4

Tananbaum James B. · CIK 0001581754 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 680,486

F6 · kind: Represents shares received by TFL Investment Holdings, LLC ("TFL") pursuant to pro rata distributions by Labs, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act.

F7 · ownership.nature: The shares are held of record by TFL. Tananbaum is the manager of TFL, and James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust, of which Tananbaum is a trustee, is the sole member of TFL.

SEC source: 0001104659-26-039609 · tm2611109-1_4seq1.xml · nonDerivative · entry 3

Tananbaum James B. · CIK 0001581754 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F5 · kind: Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Labs to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act.

F4 · ownership.nature: The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs, except to the extent of his pecuniary interest in such securities.

SEC source: 0001104659-26-039609 · tm2611109-1_4seq1.xml · nonDerivative · entry 2

Tananbaum James B. · CIK 0001581754 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,123,337

F3 · kind: Represents shares received by Labs pursuant to pro rata distributions by Labs Affiliates, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act.

F4 · ownership.nature: The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs, except to the extent of his pecuniary interest in such securities.

SEC source: 0001104659-26-039609 · tm2611109-1_4seq1.xml · nonDerivative · entry 1

Tananbaum James B. · CIK 0001581754 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · kind: Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Foresite Labs Affiliates 2021, LLC ("Labs Affiliates") to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · ownership.nature: The shares are held of record by Labs Affiliates. Foresite Labs, LLC ("Labs") is the managing member of Labs Affiliates and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), a manager of Labs, may be deemed to share voting and dispositive power over such shares. Tananbaum disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs Affiliates, except to the extent of his pecuniary interest in such securities.

SEC source: 0002023806-26-000003 · form4-01292026_120158.xml · derivative · entry 1

Pangali Sanam · CIK 0002023806 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,200

Underlying: Common Stock · 186,200 shares

Expires 2036-01-25

F1 · derivative.exercise_date: 25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date.

SEC source: 0002023657-26-000003 · form4-01292026_120147.xml · derivative · entry 1

Bradley Mark Christopher · CIK 0002023657 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,225

Underlying: Common Stock · 190,225 shares

Expires 2036-01-25

F1 · derivative.exercise_date: 25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date.

SEC source: 0001435618-26-000003 · form4-01292026_120158.xml · derivative · entry 1

Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 745,875

Underlying: Common Stock · 745,875 shares

Expires 2036-01-25

F1 · derivative.exercise_date: 25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date.

SEC source: 0001506218-26-000003 · form4-01292026_120145.xml · derivative · entry 1

Hardiman Roy C. · CIK 0001506218 · Chief Business & Strategy Ofcr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,875

Underlying: Common Stock · 190,875 shares

Expires 2036-01-25

F1 · derivative.exercise_date: 25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date.

SEC source: 0001789317-26-000003 · form4-01292026_120144.xml · derivative · entry 1

Drappa Jorn · CIK 0001789317 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,450

Underlying: Common Stock · 221,450 shares

Expires 2036-01-25

F1 · derivative.exercise_date: 25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date.

SEC source: 0001744578-26-000003 · form4-01292026_120143.xml · derivative · entry 1

Schroer John R. · CIK 0001744578 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,225

Underlying: Common Stock · 202,225 shares

Expires 2036-01-25

F1 · derivative.exercise_date: 25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date.

SEC source: 0001751719-26-000003 · form4-01292026_120134.xml · derivative · entry 1

Goldstein David M · CIK 0001751719 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 216,675

Underlying: Common Stock · 216,675 shares

Expires 2036-01-25

F1 · derivative.exercise_date: 25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date.

SEC source: 0001253170-26-000004 · form4-01132026_110101.xml · nonDerivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara Opportunity Fund, L.P.

Disclosed balance after: 1,853,488

F1 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-003018 · tm263003-3_4seq1.xml · nonDerivative · entry 2

Foresite Labs, LLC · CIK 0002027905 · 10% owner

Foresite Labs Affiliates 2021, LLC · CIK 0002028005 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 2,908,332

F2 · ownership.nature: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.